MicroCare, LLC Announces Sale of Business

MicroCare has announced that Capital Partners™, located in Norwalk, CT, completed a control investment in MicroCare, LLC in partnership with the company’s co-founder and senior management on May 28, 2020.

MicroCare will continue to operate under the MicroCare™, Sticklers™ and MicroCare Medical™ brands.

“We closed this investment in the midst of the COVID-19 crisis as the company has proven to be a strong, recession-resistant essential business, which should benefit from a growing global focus on cleanliness and increasing importance on telecom infrastructure,” said Sarah Paquet, Vice President at Capital Partners.

Tom Tattersall, former MicroCare COO, will assume the role of MicroCare CEO. He states “the sale of MicroCare was a very lengthy process to ensure we found the right fit for our company, our employees and our customers. We are pleased that Capital Partners recognizes the strengths of the MicroCare business as well as its future potential.”

“With Capital Partners on-going support, we are well-positioned to continue our sustainable, profitable growth. With further investments in product development, technology and distribution infrastructure, we remain committed to delivering a broad range of critical cleaning solutions and the value-added technical expertise and lab-support our distributors and end-users have come to expect from us.”

“MicroCare is a leader in multiple, highly-attractive industrial end markets.” said Ed Tan, Managing Director of Capital Partners, who also added, “MicroCare is a perfect fit with our approach of partnering with great managers and investing in a business with strong organic growth potential and attractive strategic acquisition opportunities.”

MicroCare, LLC is an ISO 9001:2015 registered company specializing in cleaning, coating and lubricating fluids used in the manufacture and installation of a broad range of products in the electronics, medical, fiber optic and metal finishing industries.  Since 1983 MicroCare has pioneered hundreds of environmentally progressive and sustainable products in response to their customers’ evolving cleaning and coating needs.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version